<乌鸦传媒>Sunitinib Effective in Very Rare Neuroendocrine Tumor The TKI boosted PFS in patients with malignant pheochromocytoma and paraganglioma Sep 20, 2021
<乌鸦传媒>Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
<乌鸦传媒>ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancer Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
<乌鸦传媒>Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer MONALEESA-2's "big message": 12.5-month boost in median OS with ribociclib-aromatase inhibitor Sep 19, 2021
<乌鸦传媒>Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
<乌鸦传媒>Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
<乌鸦传媒>Practice-Changing Study in Advanced Cervical Cancer Improved PFS, OS with pembrolizumab and chemo with or without bevacizumab Sep 18, 2021
<乌鸦传媒>Trastuzumab Deruxtecan: New Standard of Care in Pretreated, Advanced Breast Cancer? DESTINY-Breast03 turns in "absolutely startling" PFS in HER2-positive metastatic disease Sep 18, 2021
<乌鸦传媒>Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Sep 17, 2021
<乌鸦传媒>Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
<乌鸦传媒>Cancer Patients, COVID-19, and Long-Term Effects Preventing COVID sequelae can minimize disruption of cancer care, European study finds Sep 09, 2021
<乌鸦传媒>Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
<乌鸦传媒>Positive Anti-PD-1 Data in Gastric, Esophageal Cancer Better OS, PFS with nivolumab, pembrolizumab in advanced/metastatic disease Sep 23, 2020
<乌鸦传媒>Immunotherapy Falls Short Again in Ovarian Cancer No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab Sep 23, 2020
<乌鸦传媒>Novel Tx Helps Some Advanced Cervical Cancer Patients Three-fourths in small trial obtain disease control or better with antibody-drug conjugate Sep 22, 2020
<乌鸦传媒>No Luck for Chemo-Free Tx in First-Line Bladder Cancer Durvalumab alone or with tremelimumab no better than chemotherapy Sep 22, 2020
<乌鸦传媒>No Benefit With Anti-PD-L1 Drug in Metastatic TNBC Lack of progression-free, overall survival boost with atezolizumab contrast with prior trial Sep 22, 2020
<乌鸦传媒>Adjuvant Anti-CDK Thwarts Early Breast Cancer Recurrence Risk of invasive recurrence declines 25% in patients with high-risk disease Sep 20, 2020
<乌鸦传媒>Newly Approved Drug Boosts Survival in Metastatic TNBC Antibody-drug conjugate as third-line option improved survival, response rates Sep 20, 2020
<乌鸦传媒>Drug Active in 'Undruggable' KRAS-Mutant NSCLC Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
<乌鸦传媒>CDK4/6 Inhibition Boosts PFS in Endometrial Cancer Median PFS more than doubled by adding palbociclib to endocrine therapy Sep 19, 2020
<乌鸦传媒>Another First-Line Combo Succeeds in Advanced RCC Third immunotherapy plus TKI combination tops sunitinib Sep 19, 2020
<乌鸦传媒>First-Line Combo Boosts PFS in Untreated Bladder Cancer 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
<乌鸦传媒>New Standard in Third-Line Metastatic CRPC Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
<乌鸦传媒>Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer Misses primary endpoints but has unexpected key benefit Oct 01, 2019
<乌鸦传媒>Neoadjuvant Anti-PD-1 Boosts pCR in TNBC Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
<乌鸦传媒>Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
<乌鸦传媒>Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
<乌鸦传媒>CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancer Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
<乌鸦传媒>PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
<乌鸦传媒>Abemaciclib Offers Hope in HR+/HER2+Breast Cancer Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
<乌鸦传媒>First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
<乌鸦传媒>Advanced HCC Trial Misses OS Endpoint But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
<乌鸦传媒>Notable OS Gains with Dual Immunotherapy in Advanced NSCLC Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
<乌鸦传媒>Survival Bump with Palbociclib in HR+ Breast Cancer But benefit limited to subgroups; study may have been underpowered Oct 25, 2018
<乌鸦传媒>First-Line Anti-PD-1 Ups Survival for Advanced Head/Neck Cancer Pembrolizumab, with or without chemo, tops current standard Oct 24, 2018
<乌鸦传媒>Combination Slows Advanced RCC Avelumab-axitinib beneficial, irrespective of PD-L1 status Oct 23, 2018
<乌鸦传媒>Prostate RT Ups Overall Survival in Metastatic Disease Benefit limited to men with low disease burden Oct 22, 2018
<乌鸦传媒>PI3K Inhibitor Doubles PFS in HR+/HER2- Breast Cancer Benefit limited to patients with PIK3CA mutations Oct 22, 2018
<乌鸦传媒>Practice-Changing PARP Inhibitor Study in Ovarian Cancer "Unprecedented" increase in PFS with upfront olaparib maintenance Oct 21, 2018
